^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

cetuximab biosimilar

Associations
Company:
CinnaGen
Drug class:
EGFR inhibitor
Related drugs:
Associations
over1year
Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux® (Merck) in Metastatic Colorectal Cancer (clinicaltrials.gov)
P3, N=234, Recruiting, Cinnagen | Unknown status --> Recruiting | Trial completion date: Feb 2020 --> Feb 2026 | Trial primary completion date: Nov 2019 --> Nov 2025
Enrollment open • Trial completion date • Trial primary completion date • Metastases
|
EGFR (Epidermal growth factor receptor) • RAS (Rat Sarcoma Virus)
|
EGFR expression • RAS wild-type
|
Erbitux (cetuximab) • 5-fluorouracil • irinotecan • leucovorin calcium • cetuximab biosimilar